SmithKline Beckman Corp pursue three-point stragey achieve 10 pct annual increase operating earnings throughout remainder decade. In 1986 SmithKline earn 521.1 mln dlrs 6.78 dlrs share revenue 3.6 billion dlrs. The company annual report nonpharmaceutical play major role meeting earnings growth target grow faster pharmaceutical business. SmithKline whose major product antiulcer medication Tagamet report intend improve earnings exist product expand product portfolio optimize financial resources. To bolster position antiulcer market Tagamet met stiff competition SmithKline strategy develop over-the-counter version Tagamet bolster joint venture Wellcome PLC> pending venture Japan. SmithKline Allergan Inc eye skin care product division billion dlr organization five grow seven 10 pct annually. "Nondilutive acquisition real possibility" Gavin Herbert president eye skin care product report. In 1986 Allergan worldwide sale 433 mln dlrs. It Smith Kline French Laboratories pharmaceutical unit 1986 sale 1.9 billion dlrs file Food Drug Administration marketing approval cardiovascular agent include tissue plasminogen activator years. It SK F's U.S. sale force 20 pct large 1987 1000 sale personnel. Smith Kline clinical laboratory test unit 1986 sale 373 mln dlrs performs 24 mln test see increase employee drug test test AIDS antibody. Smith Kline depend share price cost money buy shares. In bought 25 pct shares. SmithKline begin management team include chief operating officer George Ebright. Reuter 